Incretin Mimetic Can Cause Severe, Disabling Joint Pain, FDA Warns

(August 31, 2015, 2:10 PM EDT) -- SILVER SPRING, Md. — Incretin mimetic diabetes drug Januvia, Onglyza and Tradjenta can cause severe and disabling joint pain, the Food and Drug Administration warned Aug. 28.

In a drug safety communication, the FDA said it has added a new warning and precaution about the risk of joint pain to the labels of all prescription drugs in the class, also known as dipeptidyl peptidase-4 (DPP-4) inhibitors.

The drugs are prescribed to patients with type 2 diabetes to help lower blood sugar.

4 Brand Groups Affected...
To view the full article, register now.